| abstract |
Methods have been presented to attenuate the myelosuppressive side effects of treatment regimens, promote thrombopoiesis and neutrophil production, and increase the effectiveness of treatment regimens by administering PF4 interacting heparinoids. In certain embodiments, the patient treatment regimen includes chemotherapy and / or radiation therapy and / or antibody therapy. In an exemplary embodiment, the patient treatment regimen is a chemotherapeutic regimen comprising gemcitabine and nab-paclitaxel. In an exemplary embodiment, the patient treatment regimen is a chemotherapeutic regimen comprising ifosfamide, carboplatin and etoposide, optionally comprising rituximab. |